GlaxoSmithKline Pharmaceuticals Limited vs Pfizer Limited
An objective side-by-side of GLAXO and PFIZER, both in Pharmaceuticals - Multinational: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-05 close
Latest results: GLAXO Sep 2026 · PFIZER Sep 2026
At a glance
- GlaxoSmithKline Pharmaceuticals Limited is the larger company by market value, about 2.4 times the size of Pfizer Limited.
- On trailing earnings, Pfizer Limited trades at the lower P/E (20.5 against 36.9).
- GlaxoSmithKline Pharmaceuticals Limited earns the higher return on equity (61.0% against 19.6%).
- Over three years GlaxoSmithKline Pharmaceuticals Limited has grown profits faster (18% a year against 8%).
- Over the past year the share prices returned -4.6% (GLAXO) and -27.5% (PFIZER).
| Metric | GlaxoSmithKline Pharmaceuticals GLAXO |
Pfizer PFIZER |
|---|---|---|
| Size and price | ||
| Market cap | ₹42,355 Cr | ₹17,644 Cr |
| Share price | ₹2,500.20 | ₹3,856.90 |
| Valuation | ||
| P/E | 36.94 | 20.53 |
| P/B | 22.52 | 4.02 |
| EV/EBITDA | 29.86 | 18.33 |
| PEG | 2.05 | 2.57 |
| Dividend yield | 2.3% | 2.0% |
| Profitability | ||
| ROE | 61.0% | 19.6% |
| ROCE | 61.0% | 24.0% |
| Operating margin | 34.1% | 36.7% |
| Sales (TTM) | ₹4,158 Cr | ₹2,654 Cr |
| Net profit (TTM) | ₹1,147 Cr | ₹859 Cr |
| Growth | ||
| Latest quarter sales YoY | +20.8% | +13.2% |
| Latest quarter profit YoY | +30.7% | +65.7% |
| Sales CAGR 3Y | +6.0% | +1.0% |
| Profit CAGR 3Y | +18.0% | +8.0% |
| Sales CAGR 5Y | +5.0% | +2.0% |
| Profit CAGR 5Y | +15.0% | +9.0% |
| Financial strength | ||
| Debt/Equity | 0.02 | 0.04 |
| Interest cover | 420.19 | 94.11 |
| Ownership | ||
| Promoter holding | 75.0% | 63.9% |
| Promoter change (4 qtrs) | +0.00 pp | +0.00 pp |
| Price performance | ||
| Return 1M | -9.25% | +0.12% |
| Return 3M | -2.70% | -21.42% |
| Return 1Y | -4.63% | -27.47% |
| Return YTD | +1.08% | -22.67% |
| Technical condition | ||
| Technical score | 24 | 55 |
| RS rating (1-99) | 63.00 | 20.00 |
| % vs 200-DMA | -0.63% | -15.56% |
| RSI (14) | 41.56 | 50.27 |
| % from 52-week high | -19.88% | -27.76% |
